Ken Griffin 4 D Molecular Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$17.03 - $35.87 $27,248 - $57,391	-1,600 Reduced 26.23%	4,500 $143,000
Q4 2023 Feb 14, 2024	BUY	$9.76 - $21.25 $6,832 - $14,875	700 Added 12.96%	6,100 $123,000
Q3 2023 Nov 14, 2023	SELL	$12.64 - $19.76 $83,424 - $130,416	-6,600 Reduced 55.0%	5,400 $68,000
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $9,096 - $13,956	600 Added 5.26%	12,000 $216,000
Q1 2023 May 15, 2023	BUY	$15.45 - $23.19 $30,900 - $46,380	2,000 Added 21.28%	11,400 $195,000

Q4 2022 Feb 14, 2023	BUY	$6.85 - $25.46 $64,390 - $239,324	9,400 New	9,400 $208,000

157

50.3M

718K

370K

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $666M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.